Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Anti-LINGO MS Study Failure Removes Upside

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.

You may also be interested in...



Spotlight Returns To Biogen R&D To Sustain Success

After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.

Vertex Readies For Commercial Future For Multi-Therapeutic Area R&D Strategy

Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.

Merck & Co. Remains 'Very Confident' In TIGIT

Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel